Navigation Links
Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
Date:5/8/2013

ponse was shown to correlate with good clinical outcomes, including improved overall survival.

The improved RNA amplification process is being used in Argos Therapeutics' ADAPT Phase 3 clinical study for AGS-003, the company's most advanced product candidate. To create AGS-003, RNA is isolated from a small tumor sample obtained from standard tumor removal surgery (nephrectomy), and dendritic cells are taken during a single leukapheresis procedure. The tumor RNA is used to "program" the dendritic cells with the entire disease-antigen repertoire to trigger an immune response against the patient's specific cancer. These antigen-loaded dendritic cells are formulated into a ready-to-use, intradermal injection.

For more information about AGS-003 and the ADAPT study, visit www.ADAPTkidneycancer.com.

About the Arcelis™ Technology Platform

Arcelis is a fully personalized, active immunotherapy technology that captures all antigens, including mutated and variant antigens that are specific to each patient's disease. It has been shown to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that are associated with toxicity. The technology can be leveraged to manufacture personalized therapies for any cancer or infectious disease.

The Arcelis process integrates readily into many current treatment paradigms, using only a small tumor or blood sample and the patient's own dendritic cells, which are derived and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient sample to program the dendritic cells to target the entire disease-antigen repertoire. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered as an intradermal injection to produce the desired patient-specific immune response.

Arcelis technology also overcomes many of the manufact
'/>"/>

SOURCE Argos Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
4. New CDC Study Confirms Effectiveness of UV-C Disinfection in Reducing Harmful Pathogens for Hospitals
5. Lilly Confirms Date and Conference Call for First-Quarter 2013 Financial Results Announcement
6. Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
7. Perrigo Confirms FDA Approval For Testosterone Gel 1%
8. New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease
9. Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Sciences Approach to Development of CS-TATI-1 to Inhibit Kaposi Sarcoma
10. Quest Diagnostics Confirms Investor Day on November 16
11. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... CytRx Corporation (Nasdaq: CYTR ), ... today announced that study designs and progress from two ... pivotal global Phase 3 clinical trial in relapsed/refractory soft ... trial in small cell lung cancer, will be presented ... Congress being held September 26-30, in Madrid, ...
(Date:9/22/2014)... Nepstar Chain Drugstore Ltd. (NYSE: NPD ) ("Nepstar" or ... based on the number of directly operated stores, today ... Shareholders (the "AGM") on October 22, 2014 at 10:00 a.m. Beijing ... the Company at 6th Floor, Tower B, Xinnengyuan Building, Nanhai Road, ... 518054, People,s Republic of China . ...
(Date:9/20/2014)... OTTAWA , Sept. 20, 2014 /CNW/ - The issue: ... voluntarily recalling all lots of its Mylan-Nitro Spray 0.4 mg/metered ... is part of the pump component. A ... delivery of nitroglycerin to the patient. This defect may lead ... fact they are unable to access it. Not receiving nitroglycerin ...
Breaking Medicine Technology:CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 2Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2
... ALEXANDRIA, Va., March 1, 2012  The National Community ... campaign launched today by the Pharmaceutical Care Management ... (PBMs). (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... said NCPA Senior Vice President for Government Affairs John ...
... PARSIPPANY, N.J., March 1, 2012  PDI, Inc. (Nasdaq: ... its fourth quarter and full year 2011 financial results ... and host a conference call on Thursday, March 8, ... information: ,  Date:Thursday, March 8, 2012Time:8:30 am Eastern timeDial-in ...
Cached Medicine Technology:NCPA Blasts Irresponsible Ad by PBM Lobby as an Affront to Fighting Drug Diversion, Pharmacy Crime 2NCPA Blasts Irresponsible Ad by PBM Lobby as an Affront to Fighting Drug Diversion, Pharmacy Crime 3
(Date:9/22/2014)... (PRWEB) September 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... County-Benson Hospital (SCBH) in Benson, Minn. The top executive ... has recently placed more than 900 healthcare executives into ... serves the residents of Swift County, Benson and the ...
(Date:9/22/2014)... NY (PRWEB) September 22, 2014 ... Beth Schrope , NewYork-Presbyterian/Columbia University Medical Center ... islet surgery, to prevent diabetes in patients who ... first center in the New York metropolitan area ... roughly 87,000 people in the United States receive ...
(Date:9/22/2014)... September 22, 2014 The ... Winter & Alvin has just been released to ... the personal development community. The media attention surrounding ... HonestyFirstReviews.com's Tiffany Hendricks prompting an investigative review. , ... great interest for many entrepreneurs and others interested ...
(Date:9/22/2014)... September 22, 2014 Purchasing greenhouse starter ... helps ensure a positive outcome. Gothic Arch ... making them a leader in the industry and a ... , third generation owner of Gothic Arch Greenhouses, it’s ... needed. Warm, moist, controlled air created inside a greenhouse ...
(Date:9/22/2014)... 22, 2014 One key emerging trend ... are investing in R&D to develop new and advanced ... biomaterial implants. The introduction of third-generation orthopedic biomaterials such ... drugs will increase the growth of the market in ... Biomaterials market to grow at a CAGR of ...
Breaking Medicine News(10 mins):Health News:Swift County-Benson Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Swift County-Benson Hospital Retains B. E. Smith to Recruit New CEO 3Health News:New Treatment May Prevent Diabetes After Pancreatitis Surgery 2Health News:New Treatment May Prevent Diabetes After Pancreatitis Surgery 3Health News:"The Millionaire's Brain" - A Review Examining Winter & Alvin's Training Course Released 2Health News:Gothic Arch Greenhouses provides the Answers to the Many Questions and Considerations of Greenhouse Ownership 2Health News:Gothic Arch Greenhouses provides the Answers to the Many Questions and Considerations of Greenhouse Ownership 3Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 2Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 3Health News:Orthopedic Biomaterials Market to Grow at 10.78% CAGR by 2018, Forecasts a New Research Report at ReportsnReports.com 4
... have developed the first genetically altered monkey model that ... according to a new study funded by the National ... understand this complex, devastating and incurable genetic disorder affecting ... advance of online publication edition of Nature, could lead ...
... could offer therapy option for cancer patients ... medical techniques, it may be possible to create replacement ... to cancer. , That,s the conclusion of U.S. researchers ... Replacement bladders made from intestinal tissue have proven successful ...
... Men who come to the hospital with pneumonia generally are ... over the next year, despite aggressive medical care, according to ... International Conference of the American Thoracic Society. Scientific sessions are ... well known that women live longer than men. We have ...
... post-traumatic stress disorder (PTSD) among caregivers of deceased ... than in the average population, according to researchers ... well as their perceptions of the transplant recipients ... presented at the American Thoracic Societys 2008 International ...
... Study finds mortality and survival rates equal for both ... Minimally-invasive laparoscopic surgery and open surgery for colon cancer ... from 12 international studies involving over 3,300 patients. ... afraid that laparoscopy might impair survival in colorectal cancer ...
... aftermath of central China,s,earthquake, up to 50,000 people ... 150,000 were injured. An estimated 10 million people ... their homes. With great sorrow for,these widespread losses ... US$30,000, for a total of US$50,000. With contributions ...
Cached Medicine News:Health News:Researchers develop first transgenic monkey model of Huntington's disease 2Health News:Replacement Bladder Grown From Body's Own Cells 2Health News:Men at increased risk of death from pneumonia compared to women 2Health News:Depression and PTSD symptoms in caregivers of lung transplant patients 2Health News:Outcomes Similar for Laparoscopic, Open Colon Cancer Surgeries 2Health News:Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China 2
... Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides a new ... The latest in Fujinon engineering combines ... guide, and a wide 90 degree field ... distal tip diameter. In addition, the ...
... Tip Laryngoscopes are the most ... The articulating tip aids during ... improved view of epiglottis. Available ... styles. We guarantee your complete ...
German Style MacIntosh Fiber Optic Blade Laryngoscopes...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: